论文部分内容阅读
目的探究厄贝沙坦与硝苯地平缓释片治疗原发性高血压的临床疗效及安全性。方法随机选取我院收治的高血压患者120例,将患者随机分为厄贝沙坦组、硝苯地平缓释片组和联合组,分别给予厄贝沙坦、硝苯地平缓释片、厄贝沙坦联合硝苯地平缓释片治疗。比较对三组患者治疗前后的收缩压、舒张压、不良反应发生率之间的差别。结果经过治疗后所有患者收缩压及舒张压都得到了显著降低(P<0.05),联合组下降幅度最大,明显高于厄贝沙坦组、硝苯地平缓释片组,差异具有统计学意义(P<0.05);所有患者均未出现明显严重不良反应。结论厄贝沙坦联合硝苯地平缓释片在治疗原发性高血压的过程中比单独使用两种药物更有效,而且无明显不良反应的发生,也具有更高的有效性及安全性。
Objective To investigate the clinical efficacy and safety of irbesartan and nifedipine sustained-release tablets in the treatment of essential hypertension. Methods A total of 120 hypertensive patients admitted to our hospital were selected randomly. The patients were randomly divided into irbesartan group, nifedipine sustained-release tablets group and combined group, and were given irbesartan, nifedipine sustained-release tablets, Beisitan combined with nifedipine sustained release tablets. Comparison of the three groups before and after treatment of systolic blood pressure, diastolic blood pressure, the difference between the incidence of adverse reactions. Results After treatment, systolic blood pressure and diastolic blood pressure of all patients were significantly reduced (P <0.05), and the combined group had the largest decrease, which was significantly higher than that of irbesartan and nifedipine sustained-release tablets, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in all patients. Conclusion Irbesartan combined with nifedipine sustained-release tablets in the treatment of essential hypertension than the two drugs alone more effective, but no obvious adverse reactions, but also has a higher effectiveness and safety.